MDGL Quote, Financials, Valuation and Earnings

Scholar Rock Holding has a net margin of -57.51% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -63.91% beat Scholar Rock Holding's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $414.07, signalling upside risk potential of 22.77%. On the other hand Scholar Rock Holding has an analysts' consensus of $50.50 which suggests that it could grow by 51.38%. Given that Scholar Rock Holding has higher upside potential than Madrigal Pharmaceuticals, analysts believe Scholar Rock Holding is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.403, which suggesting that the stock is 140.327% less volatile than S&P 500. In comparison Scholar Rock Holding has a beta of 0.592, suggesting its less volatile than the S&P 500 by 40.765%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Scholar Rock Holding pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $103.3M, which are larger than Scholar Rock Holding quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$59.4M is higher than Scholar Rock Holding's net income of -$66.5M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Scholar Rock Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is -- versus 70.41x for Scholar Rock Holding. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals has a net margin of -57.51% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -63.91% beat Terns Pharmaceuticals's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $414.07, signalling upside risk potential of 22.77%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.06 which suggests that it could grow by 510.98%. Given that Terns Pharmaceuticals has higher upside potential than Madrigal Pharmaceuticals, analysts believe Terns Pharmaceuticals is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.403, which suggesting that the stock is 140.327% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $103.3M, which are larger than Terns Pharmaceuticals quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$59.4M is lower than Terns Pharmaceuticals's net income of -$21.8M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is -- versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -57.51% compared to Madrigal Pharmaceuticals's net margin of 40.94%. Madrigal Pharmaceuticals's return on equity of -63.91% beat United Therapeutics's return on equity of 20.21%.

Madrigal Pharmaceuticals has a consensus price target of $414.07, signalling upside risk potential of 22.77%. On the other hand United Therapeutics has an analysts' consensus of $396.46 which suggests that it could grow by 28.71%. Given that United Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe United Therapeutics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.403, which suggesting that the stock is 140.327% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.638, suggesting its less volatile than the S&P 500 by 36.156%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $103.3M, which are smaller than United Therapeutics quarterly revenues of $735.9M. Madrigal Pharmaceuticals's net income of -$59.4M is lower than United Therapeutics's net income of $301.3M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is -- versus 5.19x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -57.51% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -63.91% beat Viking Therapeutics's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $414.07, signalling upside risk potential of 22.77%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 276.97%. Given that Viking Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.403, which suggesting that the stock is 140.327% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $103.3M, which are larger than Viking Therapeutics quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$59.4M is lower than Viking Therapeutics's net income of -$35.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.